KB-1064

Relatlimab

46615

Background of Relatlimab

Relatlimab, also known as BMS-986016, is a specific antibody that targets LAG3 and is derived from fully human immunoglobulin genes expressed in transgenic mice. This antibody is expressed as an immunoglobulin G4 (IgG4) type and contains a stabilizing hinge mutation (S228P). Relatlimab is the first humanized monoclonal antibody that targets LAG3 and is the most advanced in clinical development compared to other similar antibodies.

Specifications

Catalog Number	KB-1064
Antibody Name	Relatlimab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	LAG3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Durham NM, Nirschl CJ, Jackson CM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS One 2014;9(11):e109080-e109080.
Lipson E, Gopal A, Neelapu SS, et al. Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies. J Immunother Cancer 2016;4:Suppl 1:232-232. abstract.